Winnipeg, [April 2nd, 2024]. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”) is pleased to provide an interim update on the recently completed human trial at The Ottawa Hospital where Cytophage bacteriophages were used to treat a patient with an antibiotic-resistant prosthetic joint infection.